Scottish Spinraza Access – letter to Biogen

Following, The Scottish Medicines Consortium Committee announcement of their decision to accept Spinraza for restricted use in NHS Scotland in infantile onset Type I SMA only, ourselves and our SMA partner organisations have collectively written to Biogen’s management to request a review of pricing and resubmission in order to enable further progress and access for SMA Types 2 and 3. You can read the letter here.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.